AI to Boost Scientific Discovery

Key Concepts

• Tech Bio: The convergence of technology, particularly AI and data science, with biology and life sciences.
• AI-Supercharged Healthcare: The application of Artificial Intelligence to revolutionize healthcare and life sciences.
• Scientific Data as an Information Industry: The shift in biology from a purely lab-based discipline to one heavily reliant on data management and analysis.
• Value Chain in Life Sciences: The entire process from research and discovery to manufacturing and deployment of therapies.
• Incumbents vs. Startups: The dynamic between established large companies and new, agile companies in the market.
• AI Native Development: Building solutions from the ground up with AI capabilities integrated from the start.

The Transformation of Life Sciences and AI

The discussion highlights a significant transformation occurring in the life sciences and AI sectors, presenting a compelling "why now" for investors. This transformation is driven by three key factors: the availability of data, the sophistication of AI models, and a strong "industry pull" from the life sciences sector itself. This confluence of factors is poised to unlock an estimated $4 trillion worth of value across life sciences and healthcare.

Biology as a Data and Information Industry ("Tech Bio")

A fundamental shift is occurring where biology is no longer solely a "wet lab discipline" but is evolving into a data and information industry, often referred to as "tech bio." This evolution is particularly exciting for pre-seed and seed investors, especially those based in Boston, as it opens up a vast new landscape of software investing opportunities within the scientific domain.

The $4 Trillion Opportunity: Fueling Value Creation

The $4 trillion figure is pegged on the potential to drastically reduce the time and cost associated with drug development. Currently, developing a single drug can cost between $2 to $3 billion and take decades. The prospect of reducing these costs and timelines to a fraction of their current levels promises enormous economic and human impact. This opportunity spans the entire value chain in life sciences, including:

• Research and Discovery: Accelerating the identification of new therapeutic targets and compounds.
• Preclinical and Clinical Trials and Services: Streamlining the testing and validation phases.
• Manufacturing: Optimizing production processes.
• Development and Deployment: Enhancing the delivery and accessibility of therapies.

Signs of Transformation and Leveraging Software Companies

The signs of this transformation are evident across various players in the market. Major pharmaceutical companies are actively making moves in this space due to significant pressures:

• Rising R&D Costs: Costs are doubling approximately every nine years.
• Margin Issues: Facing challenges in maintaining profitability.
• Revenue Cliff: A potential $260 billion revenue cliff looms as patents expire.

These pressures are creating a strong market pull for innovative solutions. Pharmaceutical giants are increasingly partnering with startups to leverage new technologies.

Example: Takeda and Tetra Science Partnership

A notable example is Takeda's partnership with Tetra Science, a company in which the speaker is invested. Tetra Science is described as "the Snowflake specifically for scientific data." This company is collaborating with major technology players like Google, Microsoft, and Databricks to build a technology stack that can unlock scientific data, making it usable by AI models.

• Impact of the Takeda-Tetra Science Partnership:
  • Working on hundreds of use cases.
  • Driving 90% faster workflows.
  • Achieving a 40% increase in productivity.

This demonstrates the tangible adoption and benefits being realized through such collaborations.

Startups vs. Incumbents: Competition and Collaboration

A common question arises regarding how portfolio companies compete with large AI players like Anthropic. The perspective presented is that while incumbents have advantages in data and distribution, startups possess the crucial advantages of focus and speed.

Examples of Focused Startups:

• Terra Flow: A company invested in that automates the analysis and data surrounding flow cytometry, a highly specialized area.
• Tetra Science: As mentioned, focused on unifying scientific data.

These companies thrive due to their deep domain expertise and the ability to build solutions in an "AI native" way from the ground up.

The speaker argues that the landscape is not a zero-sum game. Even large AI providers like OpenAI will require partners for practical implementation. Therefore, there is significant opportunity for collaboration between startups and incumbents. The key for startups lies in their ability to address very specific domain needs with specialized talent and an AI-first approach.